Goldman Sachs Group Inc Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	BUY	$144.95 - $152.29 $49.8 Million - $52.3 Million	343,671 Added 47.82%	1,062,350 $161 Million
Q3 2022 Nov 10, 2022	BUY	$144.95 - $152.29 $49.8 Million - $52.3 Million	343,671 Added 47.82%	1,062,350 $161 Million
Q2 2022 May 14, 2024	BUY	$83.14 - $145.99 $59.8 Million - $105 Million	718,679 New	718,679 $105 Million
Q2 2022 Aug 15, 2022	BUY	$83.14 - $145.99 $28.7 Million - $50.5 Million	345,694 Added 92.68%	718,679 $105 Million
Q1 2022 May 16, 2022	BUY	$110.08 - $142.92 $14.8 Million - $19.2 Million	134,599 Added 56.46%	372,985 $44.2 Million
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $11.2 Million - $16.6 Million	111,844 Added 88.38%	238,386 $32.9 Million
Q3 2021 Nov 10, 2021	BUY	$98.85 - $138.91 $12.5 Million - $17.6 Million	126,542 New	126,542 $17.6 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.